Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.44 |
| ▸ | DRD2 | P14416 | 5/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2783595 | 0.86 | RBP4 (0.58) | RBP4DRD2 | |
| SCHEMBL2783947 | 0.86 | DRD2 (0.54) | DRD2SLC6A4 | |
| SCHEMBL5533630 | 0.83 | DRD2 (0.39) | RBP4DRD2SLC6A4 | |
| SCHEMBL2782904 | 0.83 | RBP4 (0.43) | RBP4MEN1KMT2ADRD2GRM2 | |
| SCHEMBL24727974 | 0.82 | RBP4 (0.45) | RBP4DRD2GRM2HTR2C | |
| SCHEMBL2784893 | 0.81 | MEN1 (0.46) | RBP4MEN1KMT2ADRD2SLC6A4 | |
| SCHEMBL2783346 | 0.81 | MEN1 (0.46) | RBP4MEN1KMT2ADRD2SLC6A4 | |
| SCHEMBL2781323 | 0.80 | DRD3 (0.45) | RBP4DRD2GRM2SLC6A4HRH1 | |
| SCHEMBL2783115 | 0.78 | MAP3K12 (0.45) | RBP4DRD2GRM2SLC6A4HRH1 | |
| SCHEMBL2781711 | 0.78 | DRD3 (0.43) | RBP4DRD2GRM2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2010-10-07 | — | — | US | claimed |
| EP-2204363-A1 | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-07-07 | — | — | EP | claimed |
| CN-1997630-A | New disubstituted phenylpiperidines as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2007-07-11 | — | — | CN | claimed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | claimed |
| CN-1997630-B | New disubstituted phenylpiperidines as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB | 2013-01-30 | — | — | CN | disclosed |
| US-8314126-B2 | Disubstituted phenylpiperdines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2012-11-20 | — | — | US | disclosed |
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2010-10-07 | — | — | US | disclosed |
| US-7763639-B2 | Disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2010-07-27 | — | — | US | disclosed |
| EP-2204363-A1 | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-07-07 | — | — | EP | disclosed |
| CN-1997630-A | New disubstituted phenylpiperidines as modulators of dopamine neurotransmission | NEUROSEARCH SWEDEN AB (SE) | 2007-07-11 | — | — | CN | disclosed |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | SANIONA AB (DK) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256163-A1 | DISUBSTITUTED PHENYLPIPERDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | RBP4 2682/4885MEN1 4071/4885KMT2A 1894/4885 |
| US-20070149542-A1 | DISUBSTITUTED PHENYLPIPERIDINES/PIPERAZINES AS MODULATORS OF DOPAMINE NEUROTRANSMISSION | DRD2, DRD4, DRD1 | RBP4 2691/4885MEN1 4097/4885KMT2A 2315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.